Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Novartis AG

Kepler Capital analyst David Evans maintained a Buy rating on Novartis AG on November 21 and set a price target of CHF106.00. The company’s shares ...

Kepler Capital  Keeps Their Buy Rating on Novartis AG (NOVN)

Cineverse ( ($CNVS) ) has issued an announcement. On November 20, 2025, Cineverse Corp. amended its 2017 Equity Incentive Plan to increase the numb...

Cineverse Amends Equity Plan and Elects Board Members

Morgan Stanley analyst Thibault Boutherin maintained a Buy rating on Novartis AG yesterday. The company’s shares closed today at CHF100.42. Bouther...

Morgan Stanley Reaffirms Their Buy Rating on Novartis AG (NOVN)

Bernstein analyst Florent Cespedes maintained a Buy rating on Novartis AG yesterday and set a price target of CHF108.00. Cespedes covers the Health...

Bernstein Keeps Their Buy Rating on Novartis AG (NOVN)

Alliance Global Partners analyst Brian Kinstlinger maintained a Buy rating on Cineverse on November 18 and set a price target of $6.00. The company...

Alliance Global Partners Keeps Their Buy Rating on Cineverse (CNVS)

Olema Pharmaceuticals stock rallied on Tuesday alongside an update from rival drugmaker Roche.


Why Is Olema Pharmaceuticals Stock (OLMA) Up Today?

Berenberg Bank analyst Luisa Hector maintained a Hold rating on Novartis AG today and set a price target of CHF92.00. According to TipRanks, Hector...

Berenberg Bank Sticks to Its Hold Rating for Novartis AG (NOVN)

In a report released on November 14, David Evans from Kepler Capital maintained a Buy rating on Novartis AG, with a price target of CHF106.00. The ...

Novartis AG (NOVN) Receives a Buy from Kepler Capital

Cineverse Corp. (($CNVS)) has held its Q2 earnings call. Read on for the main highlights of the call. Cineverse Corp.’s recent earnings call painte...

Cineverse Corp. Earnings Call: Growth Amid Challenges

In a report released today, Sumant Kulkarni from Canaccord Genuity maintained a Buy rating on Annovis Bio, with a price target of $17.00. According...

Canaccord Genuity Reaffirms Their Buy Rating on Annovis Bio (ANVS)

Several pharmaceutical companies awaiting a decision from U.S. authorities on their drug applications are set to get them this month. These decisio...

REGN, GMAB, ARWR: Which Healthcare Stock Is Best Buy Ahead of U.S. Drug Approvals This Nov?

Shares in Swiss pharmaceutical giant Novartis ($NVS) were looking healthier today after hailing a generational breakthrough in the battle against t...

Novartis Stock (NVS) Doesn’t Suck as it Hails Generational Anti-Malaria Drug

Nevada Sunrise Gold ( ($TSE:NEV) ) just unveiled an update. Nevada Sunrise Metals Corporation has announced an expanded advertising and investor aw...

Nevada Sunrise Expands Investor Awareness Campaign with INN

An announcement from Nevada Sunrise Gold ( ($TSE:NEV) ) is now available. Nevada Sunrise Metals Corporation has commenced its Fall 2025 exploration...

Nevada Sunrise Initiates Fall 2025 Exploration at Griffon Gold Mine

Nevada Sunrise Gold ( ($TSE:NEV) ) has provided an announcement. Nevada Sunrise Metals Corporation has commenced its Fall 2025 exploration program ...

The latest update is out from Nevada Sunrise Gold ( ($TSE:NEV) ). Nevada Sunrise Metals Corporation has announced a 14-month advertising and invest...

Nevada Sunrise Launches Investor Awareness Campaign with INN

Analysts fell to the sidelines weighing in on Edwards Lifesciences (EW – Research Report), Bicycle Therapeutics (BCYC – Research Report) and Envist...

Analysts’ Top Healthcare Picks: Edwards Lifesciences (EW), Bicycle Therapeutics (BCYC)

In a report released today, Jonathan Block from Stifel Nicolaus reiterated a Buy rating on Envista Holdings, with a price target of $25.00. The com...

Stifel Nicolaus Sticks to Its Buy Rating for Envista Holdings (NVST)

Piper Sandler analyst Jason Bednar maintained a Hold rating on Envista Holdings today and set a price target of $19.00. The company’s shares closed...

Piper Sandler Remains a Hold on Envista Holdings (NVST)

DZ BANK AG analyst Elmar Kraus maintained a Buy rating on Novartis AG today. The company’s shares opened today at CHF97.80. Kraus covers the Health...

DZ BANK AG Keeps Their Buy Rating on Novartis AG (NOVN)

In a report released yesterday, Thibault Boutherin from Morgan Stanley maintained a Hold rating on Novartis AG, with a price target of CHF108.00. T...

Morgan Stanley Sticks to Their Hold Rating for Novartis AG (NOVN)

The latest update is out from Novartis ( ($NVS) ). On October 26, 2025, Novartis announced its agreement to acquire Avidity Biosciences, a biopharm...

Novartis to Acquire Avidity Biosciences, Enhancing Neuroscience Pipeline

Bernstein analyst Florent Cespedes maintained a Buy rating on Novartis AG today and set a price target of CHF108.00. The company’s shares opened to...

Novartis AG (NOVN) Gets a Buy from Bernstein

In a report released today, Benjamin Jackson CFA from Jefferies maintained a Hold rating on Novartis AG, with a price target of CHF110.00. The comp...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NVS	$127.31	+2.37%	2.20M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NVS	$127.31	+2.4%	2.20M
3
4
5
6

NVS

NVS

Get Novartis AG Data in Excel

Get Novartis AG Data in Excel